04:52 PM EDT, 05/23/2025 (MT Newswires) -- Goodwood Fund and Puccetti Funds Management, collectively, Goodwood, said Friday that they plan to nominate six new directors for election to the board of Cosciens Biopharma ( CSCI ) at the company's annual and special meeting on June 26.

Goodwood currently owns about 8.2% of Cosciens' outstanding shares, totaling 257,257 common shares, according to the statement.

Goodwood said that without new board leadership, "Cosciens will continue its legacy of shareholder value destruction, irresponsible overspending, including on long-shot R&D programs, and broken promises. The current board of Cosciens is out of ideas and out of time."

The nominees are: President and Chief Executive of Medexus Pharmaceuticals Kenneth d'Entremont; Anthony J. Giovinazzo, former president and CEO of Cynapsus Therapeutics; Joe O'Neill, chief business officer and founder at Aeolian Biotech; Peter H. Puccetti, chairman and chief investment officer of Goodwood; Robert A. Seager, partner at Voorheis & Co. and executive vice president of Seacombe Partners; and David Spear, president and chief strategy officer of Advancing Eyecare.